跳至主要内容
临床试验/NCT02811224
NCT02811224进行中(未招募)不适用

Ovarian Cancer Hemoscope Trial

Scripps Translational Science Institute0 个研究点目标入组 50 人开始时间: 2016年5月最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
入组人数
50
主要终点
Sensitivity of an assay that detects circulating tumor DNA

研究概览

简要总结

This is a prospective, gold standard observational trial designed to enroll consecutive, consenting ovarian cancer patients for the purpose of determining sensitivity of an assay that detects circulating tumor DNA. This observational pilot trial will also be used to examine the genetic variants/mutations present in the tumor tissue DNA.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Patients with ovarian cancer undergoing surgery (all stages)
  • Over 18 years old
  • Control Group
  • Patients with a benign gynecological condition undergoing surgery
  • Over 18 years old

排除标准

  • Previous cancer diagnosis (all)
  • Radiation therapy before surgical treatment
  • Bone marrow transplant
  • Chemotherapy before surgical treatment
  • Invasive procedure resulting in damage to tissue (e.g., surgery, biopsy, thermal ablation) in the 7 days prior to baseline (pre-surgical) blood collection

结局指标

主要结局

Sensitivity of an assay that detects circulating tumor DNA

时间窗: 3 years

次要结局

未报告次要终点

研究者

发起方
Scripps Translational Science Institute
申办方类型
Other
责任方
Sponsor

相似试验